![Page 1: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/1.jpg)
Pharmacodynamics/Toxicodynamics
Elizabeth Kampira PhD
![Page 2: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/2.jpg)
What is Pharmacodynamics
• Effect of the drug on the biochemical and physiological function of the body.
• The mechanisms of drug action and the relationship between drug concentration and effect.
• L +R LR
• where L=ligand (drug), R=receptor (attachment site)
![Page 3: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/3.jpg)
Toxicodynamics
• Is the study of toxic actions of xenobiotic substances on living systems.
• It is concerned with processes and changes that occur to the drug at the target tissue, including metabolism and binding that results in an adverse effect.
• These effects are result of the interaction of the biologically effective dose of the ultimate (active) form of the toxicant with molecular target
• Simply, TD is concerned with what the toxicant do to the body
![Page 4: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/4.jpg)
Site of ActionDosage Effects
PlasmaConcen.
Pharmacokinetics Pharmacodynamics
DosageExposure
ToxicEffects
PlasmaConc.
Site ofaction
Toxicokinetics Toxicodynamics
Pharmacodynamics/Toxicodynamics
![Page 5: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/5.jpg)
Molecular Targets Concept
• The toxic action of a chemical is a consequence of thephysical/chemical interaction of the active form of
thatchemical
withorganism
a molecular
target
within
the
living
![Page 6: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/6.jpg)
Molecular
Targets
Concept
![Page 7: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/7.jpg)
Examples of Molecular Targets
Proteins––
Arylhydrocarbon(Ah) receptor—DioxinHemoglobin—COLipids—Carbon
tetrachlorideDNA—Aflatoxin
![Page 8: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/8.jpg)
Toxicodynamics
![Page 9: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/9.jpg)
![Page 10: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/10.jpg)
Why concerned with what the drug does to the body
• FDA Approved and Unapproved Uses
• Interactions with Other Drugs
• Adverse Effects and Contraindications
![Page 11: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/11.jpg)
Why concerned with what the drug does to the body
• Better assessment of new modalities for using drugs
• Better assessment of new indications for drugs
• Better assessment of new concerns regarding risk-benefit
AIDS EVALUATION OF MEDICAL LITERATURE:
![Page 12: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/12.jpg)
Why concerned with what the does to the body
• The patient has more respect for and trust in a therapist who can convey to the patient how the drug is affecting the patient’s body.
AIDS PATIENT-DOCTOR RELATIONSHIP:
• A patient who understands his/her therapy is more inclined to become an active participant in the management of the patient’s disease.
![Page 13: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/13.jpg)
Why concerned with what the drug does to the body
• Knowledge of how a drug works increases the therapist’s confidence that the drug is being used appropriately.
PEACE OF MIND!
![Page 14: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/14.jpg)
HOW DO DRUGS WORK?
• Some antagonize, block or inhibit endogenous proteins
• Some activate endogenous proteins
• A few have unconventional mechanisms of action
Most work by interacting with endogenous proteins:
![Page 15: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/15.jpg)
HOW DO DRUGS ANTAGONIZE, BLOCK OR INHIBIT ENDOGENOUS PROTEINS?
• Antagonists of Cell Surface Receptors
• Antagonists of Nuclear Receptors
• Enzyme Inhibitors
• Ion Channel Blockers
• Transport Inhibitors
•Inhibitors of Signal Transduction Proteins
![Page 16: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/16.jpg)
Toxicodynamics
• Determines the no. of receptors that can interact with toxicants
• Binding • Interaction • Induction of toxic effects
![Page 17: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/17.jpg)
Receptor (key element)
• In addition to its usefulness for explaining biology, the receptor concept has important practical consequence for The development of drugs Arriving at therapeutic decisions in clinical
practice.
![Page 18: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/18.jpg)
Macromolecular nature of drug receptors
• Regulatory proteins
• Enzymes
• Transport proteins
• Structural proteins
• The ability to bind to a receptor is mediated by the chemical structure of the drug that allows it to Interact with complementary surfaces on the receptor
![Page 19: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/19.jpg)
RECEPTOR:• A macromolecular component of the organism that binds the
drug and initiates its effect.
Cell surface receptor• A receptor that is embedded in the cell membrane and
functions to receive chemical information from the extracellular compartment and to transmit that information to the intracellular compartment
In most cases, the chemical nature of the receptor site remains obscure.
![Page 20: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/20.jpg)
HOW DO DRUGS WORK BY ANTAGONIZING CELL SURFACE RECEPTORS?
• Cell surface receptors exist to transmit chemical signals from the outside to the inside of the cell.
• Some compounds bind to cell surface receptors, yet do not activate the receptors to trigger a response.
• When cell surface receptors bind the molecule, the endogenous chemical cannot bind to the receptor and cannot trigger a response.
• The compound is said to “antagonize” or “block” the receptor and is referred to as a receptor antagonist.
![Page 21: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/21.jpg)
HOW DO DRUGS WORK BY ANTAGONIZING CELL SURFACE RECEPTORS?
Cell Membrane
Bound Endogenous Activator (Agonist) of Receptor
Active Cell Surface Receptor
Extracellular Compartment
Intracellular Compartment
Cellular Response
Displaced Endogenous Activator (Agonist) of Receptor
Inactive Cell Surface Receptor Upon being Bound
Extracellular Compartment
Intracellular Compartment
Bound Antagonist of Receptor (Drug)
![Page 22: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/22.jpg)
HOW DO DRUGS WORK BY ANTAGONIZING CELL SURFACE RECEPTORS?
Inactive Receptor
Cell Membrane
Displaced Endogenous Activator (Agonist) of Receptor
Extracellular Compartment
Intracellular Compartment
Bound Antagonist of Receptor
Allosteric Inhibitor
Active Receptor
•Angiotensin Receptor Blockers (ARBs) for high blood pressure, heart failure, chronic renal insufficiency(losartan [Cozaar®]; valsartan [Diovan®])
Are they clinically useful?
![Page 23: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/23.jpg)
HOW DO DRUGS ANTAGONIZE, BLOCK OR INHIBIT ENDOGENOUS PROTEINS?
• Antagonists of Cell Surface Receptors
• Antagonists of Nuclear Receptors
• Enzyme Inhibitors
• Ion Channel Blockers
• Transport Inhibitors
•Inhibitors of Signal Transduction Proteins
![Page 24: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/24.jpg)
HOW DO DRUGS WORK BY ANTAGONIZING NUCLEAR RECEPTORS?
Displaced Endogenous Activator (Agonist) of Nuclear Receptor
Intracellular Compartment
Nucleus
DNA
Bound Antagonist of Receptor (Drug)
Inactive Nuclear ReceptorIn Cytosolic Compartment
Inactive Nuclear ReceptorIn Nuclear Compartment
Estrogen Receptor Antagonists for the prevention and treatment of breast cancer (tamoxifen [Nolvadex®])
![Page 25: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/25.jpg)
HOW DO DRUGS ANTAGONIZE, BLOCK OR INHIBIT ENDOGENOUS PROTEINS?
• Antagonists of Cell Surface Receptors
• Antagonists of Nuclear Receptors
• Enzyme Inhibitors
• Ion Channel Blockers
• Transport Inhibitors
•Inhibitors of Signal Transduction Proteins
![Page 26: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/26.jpg)
HOW DO DRUGS WORK BY INHIBITING ENZYMES?
Active Enzyme
Substrate Product
Cellular Function
Inactive Enzyme
Substrate
Bound Enzyme Inhibitor (Drug)
•Enzymes catalyze the biosynthesis of products from substrates.
• Some drugs bind to enzymes and inhibit enzymatic activity.
• Loss of product due to enzyme inhibition mediates theeffects of enzyme inhibitors.
e.g Cyclooxygenase Inhibitors for pain relief,particularly due to arthritis (aspirin; ibuprofen [Motrin®])/ ACE
![Page 27: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/27.jpg)
HOW DO DRUGS ANTAGONIZE, BLOCK OR INHIBIT ENDOGENOUS PROTEINS?
• Antagonists of Cell Surface Receptors
• Antagonists of Nuclear Receptors
• Enzyme Inhibitors
• Ion Channel Blockers
• Transport Inhibitors
•Inhibitors of Signal Transduction Proteins
![Page 28: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/28.jpg)
ARE DRUGS THAT BLOCK IONCHANNELS CLINICALLY USEFUL?
• Calcium Channel Blockers (CCBs) for angina and high blood pressure (amlodipine [Norvasc®]; diltiazem [Cardizem®])
Some important examples:
• Sodium Channel Blockers to suppress cardiac arrhythmias (lidocaine [Xylocaine®]; amiodarone [Cordarone®])
![Page 29: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/29.jpg)
ARE DRUGS THAT INHIBIT TRANSPORTERSCLINICALLY USEFUL?
• Selective Serotonin Reuptake Inhibitors (SSRIs) for the treatment of depression (fluoxetine [Prozac®]; fluvoxamine [Luvox®])
Some important examples:
• Inhibitors of Na-2Cl-K Symporter (Loop Diuretics) in renal epithelial cells to increase urine and sodium output for the treatment of edema (furosemide [Lasix®]; bumetanide [Bumex®])
![Page 30: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/30.jpg)
•Tyrosine Kinase Inhibitors for chronic myelocytic leukemia (imatinib [Gleevec®])•Type 5 Phosphodiesterase Inhibitors for erectile dysfunction (sildenafil [Viagra®])• This is a major focus of drug development
Some important examples:
ARE DRUGS THAT INHIBIT SIGNAL TRANSDUCTION PROTEINSCLINICALLY USEFUL?
![Page 31: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/31.jpg)
HOW DO DRUGS WORK BY ACTIVATING ENDOGENOUS PROTEINS?
• Agonists of Cell Surface Receptors(e.g. alpha-agonists, morphine agonists)
• Agonists of Nuclear Receptors(e.g. HRT for menopause, steroids for inflammation)
• Enzyme Activators(e.g. nitroglycerine (guanylyl cyclase), pralidoxime)
• Ion Channel Openers(e.g. minoxidil (K) and alprazolam (Cl))
![Page 32: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/32.jpg)
HOW DO CHEMICALS WORK BY ACTIVATING CELL SURFACE RECEPTORS?KEY CONCEPTS:
•Cell surface receptors exist to transmit chemical signals from the outside to the inside of the cell.
• Some chemicals bind to cell surface receptors and trigger a response.
• Chemicals in this group are called receptor agonists.
• Some agonists are actually the endogenous chemical signal, whereas other agonists mimic endogenous chemical signals.
![Page 33: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/33.jpg)
HOW DO CHEMICALS WORK BY UNCONVENTIONAL MECHANISMS OF ACTION?
•Disrupting of Structural Proteins e.g. vinca alkaloids for cancer, colchicine for gout
• Being Enzymese.g. streptokinase for thrombolysis
• Covalently Linking to Macromoleculese.g. cyclophosphamide for cancer
• Reacting Chemically with Small Moleculese.g. antacids for increased acidity
• Binding Free Molecules or Atomse.g. drugs for heavy metal poisoning, infliximab (anti-TNF)
![Page 34: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/34.jpg)
HOW DO DRUGS WORK BY UNCONVENTIONAL MECHANISMS OF ACTION (Continued)?
•Being Nutrientse.g. vitamins, minerals
• Exerting Actions Due to Physical Propertiese.g. mannitol (osmotic diuretic), laxatives
• Working Via an Antisense Actione.g. fomivirsen for CMV retininitis in AIDS
• Being Antigens e.g. vaccines
•Having Unknown Mechanisms of Actione.g. general anesthetics
![Page 35: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/35.jpg)
Characteristics of Drug-Receptor Interactions
• Chemical Bond: ionic, hydrogen, hydrophobic, Van der Waals, and covalent.
• Saturable• Competitive• Specific and Selective • Structure-activity relationships• Transduction mechanisms
![Page 36: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/36.jpg)
Receptor Transduction Mechanisms
• Neurotransmitter and peptide signaling requires receptor‐mediated responses to affect the target cell.
• Ion channel linked receptors e.g. Ach nicotinic (Na+) and GABA (Cl-)
• Second messenger generation, adenylate cyclase stimulation or inhibition - cAMP,
guanylate cyclase - cGMP, phospholipase C - IP3, DAG
• Some receptors are themselves protein kinases• Intracellular receptors (e.g. corticosteroids,
thyroid hormone)
![Page 37: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/37.jpg)
Drug-Receptor Interactions Obey the Law Of Mass Action
effectDRRDk
k
1
2
2].[1].].[[ kDRkRD By law of mass action:
At equilibrium
][
]].[[
1
2
DR
RDK
k
kD
Therefore:
Quantitative aspects of drug-receptor interaction
K1 rate constant for combination
K2 rate constant for dissociation
KD equilibrium dissociation constant
![Page 38: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/38.jpg)
Occupancy Theory• Single-occupancy theory – The intensity of the body’s response to the drug is directly related to the number of receptors occupied by the drug. – The maximum response occurs when all of the receptors have drug molecules attached. • Modified occupancy theory – Different drugs have different strengths of attractions, or affinity, for receptor sites. – Once a drug is attached to a receptor, it has different abilities to stimulate the receptor
![Page 39: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/39.jpg)
If RT = total # of receptors, then RT = [R] + [DR]
Replace [R] by (RT -[DR]) and rearrange:
OCCUPATION THEORY OF DRUG-RECEPTOR INTERACTIONS
[DR] [D]
RT Kd + [DR]Max. effect==
EFFECTDR complex D+R
Fractional occupancy = DR = DR RT R + DR
But from KD = KD DRD
R
![Page 40: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/40.jpg)
KD
When [D] = KD
[DR] RT
= 0.5
[D]
[DR]
/Rt
0 5 10 15 200.00
0.25
0.50
0.75
1.00
][
][][
DK
D
R
DR
Dt
effect [DR] [D]
Max. effect RT Kd + [D]=
Notice how the drug effect reaches a plateau or maximum. This is because there are a finite number of receptors.
=
![Page 41: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/41.jpg)
![Page 42: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/42.jpg)
Dose-Response Concept
The magnitude of the toxic effect will be a function of the
concentration of altered molecular targets, which in turnis related to the
concentration of the active form of thetoxicant( biologically effective
dose)at th
esite
where
themolecul
artargets
are
located.
12
![Page 43: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/43.jpg)
Receptor Binding
The dose-response relationship (from C.D. Klaassen, Casarett and Doull’s Toxicology, 5th ed., New York: McGraw-Hill, 1996).
% B
ound
Concentration of Ligand
Kd
The log-dose response curve is dependent on the affinity of the ligand for the receptor and its intrinsic activity. Affinity determines the position of the dose-response curve on the X-axis, while intrinsic activity affects the magnitude of the response.
![Page 44: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/44.jpg)
[D] (concentration units)
[DR
]/RT
0.01 0.10 1.00 10.00 100.000.00
0.25
0.50
0.75
1.00
Kd=1
kd=5
Kd=0.5
Compounds Have Different Affinities for the Same Receptor
![Page 45: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/45.jpg)
Competitive Noncompetitive
Types of Receptor Antagonists
![Page 46: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/46.jpg)
[D] (concentration units)
% M
axim
al E
ffect
0.01 0.10 1.00 10.00 100.00 1000.000.0
0.2
0.4
0.6
0.8
1.0
Partial agonist
Full Agonist
Partial agonist
PARTIAL AGONISTS - EFFICACYEven though drugs may occupy the same # of receptors, the magnitude of their effects may differ.
![Page 47: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/47.jpg)
Receptor Sensitivity
• Changes in receptor sensitivity – Receptors are not static. – Continual stimulation from an agonist usually makes the drug less effective. – Continual blockage from an antagonist usually makes the drug more likely to react. • Nonreceptor responses – Drugs exert their effect by reacting physically or chemically with other molecules in the body
![Page 48: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/48.jpg)
![Page 49: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/49.jpg)
Drug (D)
Ri
DRi DRa
Ra
CONFORMATIONAL SELECTION
HOW TO EXPLAIN EFFICACY?
The relative affinityof the drug to either conformation will determine the effect of the drug
Factors Governing Drug Action1. Affinity A measure of the tightness that a drug binds to the receptor.
2.Intrinsic activity.Is a measure of the ability of a drug once bound to the receptor to generate an effect activating stimulus and producing a change in cellular activity.
![Page 50: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/50.jpg)
Spare Receptors
![Page 51: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/51.jpg)
Receptor Regulation
• Sensitization or Up-regulation1. Prolonged/continuous use of receptor blocker2. Inhibition of synthesis or release of hormone/neurotransmitter - Denervation
• Desensitization or Down-regulation1. Prolonged/continuous use of agonist2. Inhibition of degradation or uptake of agonist
Homologous vs. HeterologousUncoupling vs. Decreased Numbers
![Page 52: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/52.jpg)
GRADED DOSE-RESPONSE CURVE
ED50
ED50
![Page 53: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/53.jpg)
QUANTAL DOSE-RESPONSE CURVE
Frequency Distribution
CumulativeFrequency Distribution
![Page 54: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/54.jpg)
![Page 55: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/55.jpg)
Morphine
Aspirin
![Page 56: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/56.jpg)
THERAPEUTIC INDEX – AN INDEX OF SAFETY
Hypnosis Death
The Therapeutic Index (TI) is used to compare the therapeutically effective dose to the toxic dose
![Page 57: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/57.jpg)
Therapeutic index• The use of the ED50 and LD50 doses to derive the TI
may be misleading as to safety, depending on the slope of the dose-response curves for therapeutic and lethal effects.
• To overcome this deficiency, toxicologists often use another term to denote the safety of a drug – the Margin of Safety (MOS).
• The MOS is usually calculated as the ratio of the dose that is just within the lethal range (LD01) to the dose that is 99% effective (ED99).• The MOS = LD01/ED99. A physician must use caution in prescribing a drug in which the MOS is less than 1.
![Page 58: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/58.jpg)
Margin of Safety = LD1
ED99
ED50AED99A
LD1A
![Page 59: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/59.jpg)
Causes of Variability in Drug Response
Those related to the biological system1. Body weight and size2. Age and Sex3. Genetics - pharmacogenetics4. Condition of health5. Placebo effect
![Page 60: 3. Pharmacodymics and toxicodynamics 21_09_15.pptx](https://reader036.vdocument.in/reader036/viewer/2022062420/563db925550346aa9a9a7a4c/html5/thumbnails/60.jpg)
Causes of Variability in Drug Response
• Those related to the conditions of administration1. Dose, formulation, route of administration.2. Resulting from repeated administration of drug:
drug resistance; drug tolerance-tachyphylaxis; drug allergy3. Drug interactions:
chemical or physical; GI absorption; protein binding/distribution; metabolism (stimulation/inhibition); excretion (pH/transport processes); receptor (potentiation/antagonism); changes in pH or electrolytes.